These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32668256)

  • 1. Modeling Secondary Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Rhee JW; Yi H; Thomas D; Lam CK; Belbachir N; Tian L; Qin X; Malisa J; Lau E; Paik DT; Kim Y; Choi BS; Sayed N; Sallam K; Liao R; Wu JC
    Cell Rep; 2020 Jul; 32(2):107886. PubMed ID: 32668256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels.
    Kumfu S; Chattipakorn S; Fucharoen S; Chattipakorn N
    Drug Chem Toxicol; 2013 Jul; 36(3):329-34. PubMed ID: 23050671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy?
    Wijarnpreecha K; Kumfu S; Chattipakorn SC; Chattipakorn N
    Hemoglobin; 2015; 39(1):9-17. PubMed ID: 25572185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy.
    Oudit GY; Sun H; Trivieri MG; Koch SE; Dawood F; Ackerley C; Yazdanpanah M; Wilson GJ; Schwartz A; Liu PP; Backx PH
    Nat Med; 2003 Sep; 9(9):1187-94. PubMed ID: 12937413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Females Are Protected From Iron-Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress.
    Das SK; Patel VB; Basu R; Wang W; DesAulniers J; Kassiri Z; Oudit GY
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28115312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating
    Shemer Y; Mekies LN; Ben Jehuda R; Baskin P; Shulman R; Eisen B; Regev D; Arbustini E; Gerull B; Gherghiceanu M; Gottlieb E; Arad M; Binah O
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360639
    [No Abstract]   [Full Text] [Related]  

  • 7. Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.
    Gordan R; Wongjaikam S; Gwathmey JK; Chattipakorn N; Chattipakorn SC; Xie LH
    Heart Fail Rev; 2018 Sep; 23(5):801-816. PubMed ID: 29675595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
    Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy.
    Das SK; Wang W; Zhabyeyev P; Basu R; McLean B; Fan D; Parajuli N; DesAulniers J; Patel VB; Hajjar RJ; Dyck JR; Kassiri Z; Oudit GY
    Sci Rep; 2015 Dec; 5():18132. PubMed ID: 26638758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of iron overload on mitochondrial function, mitochondrial dynamics, and ferroptosis in cardiomyocytes.
    Sumneang N; Siri-Angkul N; Kumfu S; Chattipakorn SC; Chattipakorn N
    Arch Biochem Biophys; 2020 Feb; 680():108241. PubMed ID: 31891670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through human iPSC-derived cardiomyocytes.
    Spitalieri P; Talarico RV; Caioli S; Murdocca M; Serafino A; Girasole M; Dinarelli S; Longo G; Pucci S; Botta A; Novelli G; Zona C; Mango R; Sangiuolo F
    J Mol Cell Cardiol; 2018 May; 118():95-109. PubMed ID: 29551391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
    Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
    J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer.
    Kitani T; Ong SG; Lam CK; Rhee JW; Zhang JZ; Oikonomopoulos A; Ma N; Tian L; Lee J; Telli ML; Witteles RM; Sharma A; Sayed N; Wu JC
    Circulation; 2019 May; 139(21):2451-2465. PubMed ID: 30866650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for
    Kondo T; Higo S; Shiba M; Kohama Y; Kameda S; Tabata T; Inoue H; Okuno S; Ogawa S; Nakamura S; Takeda M; Ito E; Li J; Liu L; Kuramoto Y; Lee JK; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Circ Genom Precis Med; 2022 Oct; 15(5):e003522. PubMed ID: 35861968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the cardiac pathology of SCO2-mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell-derived cardiomyocytes.
    Hallas T; Eisen B; Shemer Y; Ben Jehuda R; Mekies LN; Naor S; Schick R; Eliyahu S; Reiter I; Vlodavsky E; Katz YS; Õunap K; Lorber A; Rodenburg R; Mandel H; Gherghiceanu M; Binah O
    J Cell Mol Med; 2018 Feb; 22(2):913-925. PubMed ID: 29193756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prooxidant mechanisms in iron overload cardiomyopathy.
    Cheng CF; Lian WS
    Biomed Res Int; 2013; 2013():740573. PubMed ID: 24350287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes.
    Shiba M; Higo S; Kondo T; Li J; Liu L; Ikeda Y; Kohama Y; Kameda S; Tabata T; Inoue H; Nakamura S; Takeda M; Ito E; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Hum Mol Genet; 2021 Jul; 30(15):1384-1397. PubMed ID: 33949662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
    Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
    Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights into the Hepcidin-Ferroportin Axis and Iron Homeostasis in iPSC-Derived Cardiomyocytes from Friedreich's Ataxia Patient.
    Bolotta A; Abruzzo PM; Baldassarro VA; Ghezzo A; Scotlandi K; Marini M; Zucchini C
    Oxid Med Cell Longev; 2019; 2019():7623023. PubMed ID: 31049138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.